LLY

1,103

-2.23%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

AZN

185.53

-0.15%↓

LLY

1,103

-2.23%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

AZN

185.53

-0.15%↓

LLY

1,103

-2.23%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

AZN

185.53

-0.15%↓

LLY

1,103

-2.23%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

AZN

185.53

-0.15%↓

LLY

1,103

-2.23%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

AZN

185.53

-0.15%↓

Home・Lista de Ações・Johnson and Johnson

Johnson and Johnson

Fechado

SetorSaúde

225.18 -2.6

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

224.96

Máximo

225.69

Indicadores-chave
By Trading Economics
Rendimento	119M 5.2B
Vendas	-502M 24B
P/E Médio do Setor	27.186 50.102
EPS	2.7
Rendimento de Dividendos	2.24
Margem de lucro	21.756
Funcionários	138,200
EBITDA	182M 6.4B

Recomendações
By TipRanks
Recomendações	Comprar
Previsão para 12 meses	+18.23% upside

Dividendos
By Dow Jones
Rendimento de Dividendos Médio do Setor	2.24% 2.33%
Próximos Ganhos	15 de jul. de 2026
Próxima data de dividendos	9 de jun. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-9.4B 564B
Abertura anterior	227.78
Fecho anterior	225.18

Sentimento de Notícias

By Acuity

63%

37%

290 / 344 Ranking em Healthcare

Johnson and Johnson Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

24 de abr. de 2026, 13:27 UTC

Aquisições, Fusões, Aquisições de Empresas

Johnson & Johnson to Acquire Atraverse Medical to Bolster Cardiac Device Portfolio

23 de abr. de 2026, 21:48 UTC

Aquisições, Fusões, Aquisições de Empresas

Regeneron Shares Up on Trump Drug Pricing Deal -- Barrons.com

22 de abr. de 2026, 11:27 UTC

Ganhos

Intuitive Surgical Earnings Show Big Beats Don't Always Spark Stock Rallies -- Barrons.com

14 de abr. de 2026, 19:38 UTC

Ganhos

Johnson & Johnson Financial Chief Sees 'Clear Line of Sight' to Double-Digit Growth by 2030 -- Barrons.com

14 de abr. de 2026, 14:13 UTC

Ganhos

Johnson & Johnson Financial Chief Sees 'Clear Line of Sight' to Double-Digit Growth by 2030 -- Barrons.com

14 de abr. de 2026, 12:57 UTC

Ganhos

Johnson & Johnson Financial Chief Sees 'Clear Line of Sight' to Double-Digit Growth by 2030 -- Barrons.com

14 de abr. de 2026, 11:19 UTC

Ganhos

Johnson & Johnson Beats Earnings Estimates. Cancer Treatments Help Drive the Quarter. -- Barrons.com

14 de abr. de 2026, 10:34 UTC

Ganhos

Johnson & Johnson Stock Rises on Earnings Beat. These Segments Boosted the Quarter. -- Barrons.com

14 de abr. de 2026, 10:20 UTC

Conversa de Mercado

Ganhos

J&J Sees Path to Double-Digit Growth by End of Decade -- Market Talk

14 de abr. de 2026, 10:20 UTC

Conversa de Mercado

Ganhos

J&J's Tremfya Sales Continue to Surge -- Market Talk

14 de abr. de 2026, 10:20 UTC

Ganhos

Johnson & Johnson: With MedTech, Anticipate Additional Rounds of VBP in China Throughout Year, Heavier in Second Half of Year >JNJ

14 de abr. de 2026, 10:20 UTC

Ganhos

Johnson & Johnson: Expect Heavier Investment in First Half of 2026 Year >JNJ

14 de abr. de 2026, 10:20 UTC

Ganhos

Johnson & Johnson: With Innovative Medicine, Expect More Pronounced Sales Impact From Newly Launched Products as 2026 Progresses>JNJ

14 de abr. de 2026, 10:20 UTC

Ganhos

Johnson & Johnson Announce Planned Enterprise Business Review for Dec. 8, 2026 >JNJ

14 de abr. de 2026, 10:20 UTC

Ganhos

Johnson & Johnson: Anticipate Higher EPS Growth in Second Half of Year Vs First Half >JNJ

14 de abr. de 2026, 10:20 UTC

Ganhos

Johnson & Johnson: With MedTech, Expect Continued Acceleration of Newly Launched Products as Year Progresses With Normalized Seasonality >JNJ

14 de abr. de 2026, 10:20 UTC

Ganhos

Johnson & Johnson: With MedTech, Surgery Transformation Sales Headwinds Expected to Increase Through Year >JNJ

14 de abr. de 2026, 10:20 UTC

Ganhos

Johnson & Johnson Sees 2026 Adjusted Operational EPS $11.30-$11.50 Vs Prior View $11.28-$11.48 >JNJ

14 de abr. de 2026, 10:20 UTC

Ganhos

Johnson & Johnson: Anticipate Fairly Consistent Operational Sales Growth in First and Second Half With 53rd Week Affecting Second Half >JNJ

14 de abr. de 2026, 10:20 UTC

Ganhos

Johnson & Johnson: With Innovative Medicine, Anticipate Generic Competition for Opsumit (Second Half in U.S.) and Simponi (First Half in EU; Potentially Second Half in U. S.) >JNJ

14 de abr. de 2026, 10:20 UTC

Ganhos

Johnson & Johnson Sees 2026 Adj. Operational Sales Growth in Range of 5.6%-6.6% Vs Prior View 5.4%-6.4% >JNJ

14 de abr. de 2026, 10:20 UTC

Ganhos

Johnson & Johnson: 1Q Innovative Medicine Operational Sales Growth Driven Primarily by Darzalex, Carvykti, Erleada, Rybrevant/Lazcluze, Tremfya and Spravato >JNJ

14 de abr. de 2026, 10:20 UTC

Ganhos

Johnson & Johnson Raises 2026 View To Sales $100.3B-$101.3B Vs Prior View $100B-$101B >JNJ

14 de abr. de 2026, 10:20 UTC

Ganhos

Johnson & Johnson 1Q Orthopaedics Sales $2.38B >JNJ

14 de abr. de 2026, 10:20 UTC

Ganhos

Johnson & Johnson: 1Q MedTech Business Growth Driven Primarily by Electrophysiology Products, Abiomed, Shockwave as Well as Trauma >JNJ

14 de abr. de 2026, 10:20 UTC

Ganhos

Johnson & Johnson Sees 2026 Operational Sales of $99.7B-$100.7B Vs Prior View $99.5B-$100.5B>JNJ

14 de abr. de 2026, 10:20 UTC

Ganhos

Johnson & Johnson 1Q Adj EPS $2.70 >JNJ

14 de abr. de 2026, 10:20 UTC

Ganhos

Johnson & Johnson: New Treatment for Bladder Cancer Inlexzo Is Outperforming All Recent Launches Based on Unique Patients Treated in First 6 Months of Approval >JNJ

14 de abr. de 2026, 10:20 UTC

Ganhos

Johnson & Johnson 1Q U.S. Sales $13.33B >JNJ

14 de abr. de 2026, 10:20 UTC

Ganhos

Johnson & Johnson 1Q International Sales $10.73B >JNJ

Comparação entre Pares

Variação de preço

Johnson and Johnson Previsão

Preço-alvo

By TipRanks

18.23% parte superior

Previsão para 12 meses

Média 266.4 USD 18.23%

Máximo 285 USD

Mínimo 250 USD

Com base em 17 analistas de Wall Street que oferecem metas de preço de 12 meses para Johnson and Johnson - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

17 ratings

Comprar

Manter

Vender

Com base em 17 analistas que deram avaliações de ações para Johnson and Johnson - Dist nos últimos 3 meses.

Sentimento

By Acuity

290 / 344 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Johnson and Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company has a collaboration agreement with Stand Up To Cancer for research testing a combination of teclistamab and daratumumab to treat a rare disease AL amyloidosis. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.